| Literature DB >> 29127509 |
Major Michael John Stacey1,2, S K Delves3, D R Woods4,5, S E Britland3, L Macconnachie6, A J Allsopp3, S J Brett4, J L Fallowfield3, C J Boos5,6.
Abstract
PURPOSE: Heat adaptation (HA) is critical to performance and health in a hot environment. Transition from short-term heat acclimatisation (STHA) to long-term heat acclimatisation (LTHA) is characterised by decreased autonomic disturbance and increased protection from thermal injury. A standard heat tolerance test (HTT) is recommended for validating exercise performance status, but any role in distinguishing STHA from LTHA is unreported. The aims of this study were to (1) define performance status by serial HTT during structured natural HA, (2) evaluate surrogate markers of autonomic activation, including heart rate variability (HRV), in relation to HA status.Entities:
Keywords: Autonomic nervous system; Catecholamines; Heat adaptation; Heat illness; Heat stroke; Metanephrine; Normetanephrine
Mesh:
Substances:
Year: 2017 PMID: 29127509 PMCID: PMC5754393 DOI: 10.1007/s00421-017-3758-y
Source DB: PubMed Journal: Eur J Appl Physiol ISSN: 1439-6319 Impact factor: 3.078
United Kingdom baseline anthropometry, VO2peak and heart rate at VO2peak for 13 volunteers who subsequently underwent serial HTT in Cyprus
| Age (years) | Height (m) | Weight (kg) | Body fat (%) |
| Peak heart rate (b min−1) |
|---|---|---|---|---|---|
| 23.4 ± 2.8 | 1.81 ± 0.07 | 80.55 ± 8.22 | 16.7 ± 4.7 | 56.5 ± 7.4 | 190 ± 9 |
Fig. 1Core temperature (Tc) and heart rate during heat tolerance test on Day 2 and Day 23 in Cyprus (Phase II). Significant difference vs. Day 23, adjusted P a< 0.0001, b< 0.0005
Core temperature (Tc), heart rate and relative perceived exertion (Borg RPE) at the start (t = 0) and end (t = 60) of heat tolerance tests in Cyprus
| Day 2 | Day 6 | Day 9 | Day 23 | |
|---|---|---|---|---|
| Tc (°C)a,b, | ||||
| | 37.0 ± 0.2* | 37.0 ± 0.2** | 37.0 ± 0.2* | 36.8 ± 0.3 |
| | 38.6 ± 0.4** | 38.3 ± 0.4** | 38.2 ± 0.4* | 37.9 ± 0.4 |
| Heart rate (b min−1)b,c | ||||
| | 83 ± 11* | 75 ± 14 | 77 ± 12 | 71 ± 15 |
| | 150 ± 13** | 138 ± 16 | 135 ± 19 | 132 ± 20 |
| Borg RPE | ||||
| | 6 (6, 7) | 6 (6, 6) | 6 (6, 6) | 6 (6, 6.5) |
| | 13 ± 3** | 12 ± 4** | 11 ± 2 | 10 ± 2 |
Significant (P < 0.001) ainteraction, bmain effect of Day, cmain effect of HTT. Significant difference from Day 23, adjusted P **< 0.01, *< 0.05
Phase II (Cyprus) measures PRE and POST heat tolerance test assessments
| Day 2 | Day 6 | Day 9 | Day 23 | |
|---|---|---|---|---|
| logRMSSDa,b,c | ||||
| PRE | 1.68 ± 0.23 | 1.65 ± 0.19 | 1.68 ± 0.20 | 1.67 ± 0.19 |
| POST | 1.34 ± 0.26** | 1.42 ± 0.17* | 1.46 ± 0.21 | 1.56 ± 0.20 |
| logLF:HFa,c | ||||
| PRE | 0.38 ± 0.3 | 0.46 ± 0.16 | 0.37 ± 0.22 | 0.51 ± 0.26 |
| POST | 0.63 ± 0.3* | 0.70 ± 0.24** | 0.55 ± 0.32 | 0.47 ± 0.27 |
| Cortisol (nmol L−1)a,b | ||||
| PRE | 413 ± 108 | 399 ± 149 | 455 ± 135 | 382 ± 85 |
| POST | 540 ± 202** | 327 ± 146 | 342 ± 162 | 334 ± 125 |
| Normetanephrine (pmol L−1)a,b,c | ||||
| PRE | 228 (176, 272) | 257 (175, 280) | 291 (253, 329) | 267 (216, 297) |
| POST | 687 ± 129** | 484 ± 113 | 574 ± 184** | 416 ± 90 |
| Metanephrine (pmol L−1)c | ||||
| PRE | 193 (154, 223) | 202 (151, 233) | 217 (156, 222) | 211 (172, 232) |
| POST | 243 ± 90 | 241 ± 63 | 243 ± 71 | 202 ± 50 |
Significant (P < 0.05) ainteraction, bmain effect of Day, cmain effect of HTT. Significant difference from the corresponding value on Day 23, adjusted P **< 0.01, *< 0.05. Heart rate variability indices: RMSSD root mean square of successive differences, LF low frequency, HF high frequency